Back to News index

Government's life sciences strategy reaction

Reacting to the publication of the Government's life sciences strategy, Mark Samuels, chief executive of Medicines UK, said:

"Generics and biosimilars account for four in every five NHS prescriptions, making them a cornerstone of patient care and an essential part of the UK's life sciences ecosystem. We welcome the recognition of their vital role in the Government's life sciences sector plan.

"The off-patent sector operates in a highly competitive global environment. To maintain supply and attract sustained investment, the UK must offer a policy and operating landscape that is both supportive and internationally attractive.

"We are encouraged by the strategy's ambition and clarity - particularly its objective to make the UK a world leader in the adoption of off-patent medicines, with a strong emphasis on biosimilars.

"A thriving off-patent sector delivers access and value for the NHS, and forms the foundation for future pharmaceutical innovation and investment. We look forward to working with Government to deliver on this important agenda."